HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment of chronic hepatitis D with interferon alpha-2b in patients with human immunodeficiency virus infection.

AbstractBACKGROUND/AIMS:
Hepatitis delta virus (HDV) coinfection is frequent in patients infected with human immunodeficiency virus (HIV), and it may cause death independently of the development of full-blown AIDS. In order to evaluate the efficacy and tolerability of interferon alpha in the treatment of hepatitis delta in HIV-infected patients, and to compare them with those observed in anti-HIV-seronegative patients, we carried out an open uncontrolled trial on 21 HIV-uninfected and 16 HIV-infected patients without severe immunodeficiency.
METHODS:
All patients were treated with recombinant interferon alpha 2b (IFN) at doses of 10 million units thrice weekly for 6 months, and 6 million units thrice weekly for an additional 6 months. Patients showing alanine transaminase activity values persistently reduced by at least 50% from basal values received an additional 1-year course of 3 million units thrice weekly.
RESULTS:
Alanine aminotransferase normalization was observed in 19% of HIV-infected and 14% of HIV-uninfected subjects during the first year; in 12% of HIV-infected and in 9% of HIV-uninfected patients during the second year. Twenty-five percent of HIV-infected and 14% of HIV-uninfected patients stopped IFN because of poor compliance or side effects. Two years after stopping interferon treatment, one anti-HIV-seropositive and two anti-HIV-seronegative patients showed complete persistent biochemical, virological and histologic remission.
CONCLUSIONS:
Long-term efficacy and toxicity of IFN treatment seem not to be different in HIV-infected and -uninfected patients with delta hepatitis; given the overall poor rate of long-term response, IFN treatment could be considered only in immunocompetent HIV-HDV-coinfected patients, strictly selected because of rapidly evolving liver disease.
AuthorsM Puoti, S Rossi, M A Forleo, S Zaltron, A Spinetti, V Putzolu, A Rodella, G Carosi
JournalJournal of hepatology (J Hepatol) Vol. 29 Issue 1 Pg. 45-52 (Jul 1998) ISSN: 0168-8278 [Print] Netherlands
PMID9696491 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Antiviral Agents
  • Hepatitis Antibodies
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Alanine Transaminase
Topics
  • Adult
  • Alanine Transaminase (blood)
  • Antiviral Agents (therapeutic use)
  • Biopsy
  • Female
  • HIV Infections (complications)
  • Hepatitis Antibodies (blood)
  • Hepatitis B (complications)
  • Hepatitis C (complications)
  • Hepatitis D, Chronic (complications, drug therapy, pathology)
  • Humans
  • Interferon alpha-2
  • Interferon-alpha (therapeutic use)
  • Male
  • Recombinant Proteins
  • Remission Induction

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: